Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib plus pirfenidone versus nintedanib alone in idiopathic pulmonary fibrosis
NL-OMON43818Phase 4Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in idiopathic pulmonary fibrosis (IPF) comparing Nintedanib + pirfenidone with Nintedanib alone (2 arms). Primary endpoint: Percentage of patients with on-treatment gastrointestinal adverse events. Started Nov 2015; status: active, not recruiting.
02
Drugs
nintedanibpirfenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON43818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43818.